Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Norfloxacin
- Accession Number
- DB01059 (APRD00469)
- Type
- Small Molecule
- Groups
- Approved
- Description
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. [PubChem]
- Structure
Structure for DB01059 (Norfloxacin)
- Synonyms
- 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure
- 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
- 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
- NFLX
- Norfloxacine
- Norfloxacino
- Norfloxacinum
- External IDs
- MK-366
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Co Norfloxacin Tablet 400 mg Oral Cobalt Laboratories 2006-07-18 Not applicable Canada 
Norfloxacin Tablet 400 mg Oral Cobalt Laboratories Not applicable Not applicable Canada Norfloxacin Tablet 400 mg Oral Pharmel Inc Not applicable Not applicable Canada Norfloxacin Tablet 400 mg Oral Aa Pharma Inc 1998-07-20 Not applicable Canada Norfloxacine-400 Tablet 400 mg Oral Pro Doc Limitee 1999-08-23 2010-07-13 Canada Noroxin Solution 3 mg Ophthalmic Merck Ltd. 1990-12-31 2005-06-18 Canada Noroxin Tablet 400 mg Oral Merck Ltd. 1986-12-31 2005-06-18 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ava-norfloxacin Tablet 400 mg Oral Avanstra Inc 2011-11-23 2014-08-21 Canada Ntp-norfloxacin Tablet 400 mg Oral Teva Not applicable Not applicable Canada PMS-norfloxacin Tablet 400 mg Oral Pharmascience Inc 2002-09-26 Not applicable Canada Riva-norfloxacin Tablet 400 mg Oral Laboratoire Riva Inc 2000-01-31 2013-07-31 Canada Riva-norfloxacin Tablet 400 mg Oral Laboratoire Riva Inc 2008-06-13 2013-07-31 Canada Teva-norfloxacin Tablet 400 mg Oral Teva 1998-08-20 Not applicable Canada - International/Other Brands
- Chibroxin
- Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antineoplastic Agents
- Chemically-Induced Disorders
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 CYP2A6 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Fluoroquinolones
- QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)
- Quinolines
- Quinolone Antibacterials
- Quinolone Antimicrobial
- Quinolones
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- UNII
- N0F8P22L1P
- CAS number
- 70458-96-7
- Weight
- Average: 319.3308
Monoisotopic: 319.133219662 - Chemical Formula
- C16H18FN3O3
- InChI Key
- OGJPXUAPXNRGGI-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
- IUPAC Name
- 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
- SMILES
- CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
Pharmacology
- Indication
For the treatment of urinary tract infection
- Structured Indications
- Pharmacodynamics
Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
- Mechanism of action
The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic that is active against both gram-positive and gram-negative bacterias. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity
Target Actions Organism ADNA topoisomerase 4 subunit A inhibitorHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) ADNA gyrase subunit A inhibitorHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UDNA topoisomerase 2-alpha inhibitorHuman - Absorption
Rapid
- Volume of distribution
- Not Available
- Protein binding
10 and 15% (Serum protein binding)
- Metabolism
Via liver and kidney
- Route of elimination
Norfloxacin is eliminated through metabolism, biliary excretion, and renal excretion. Renal excretion occurs by both glomerular filtration and tubular secretion as evidenced by the high rate of renal clearance (approximately 275 mL/min).
- Half life
3-4 hours
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Enteric bacteria and other eubacteria
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the neuroexcitatory activities of Norfloxacin. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Norfloxacin. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Norfloxacin. Experimental, Illicit Acarbose Norfloxacin may increase the hypoglycemic activities of Acarbose. Approved, Investigational Aceclofenac Aceclofenac may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Acemetacin Acemetacin may increase the neuroexcitatory activities of Norfloxacin. Approved, Experimental, Investigational Acenocoumarol Norfloxacin may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Norfloxacin. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Norfloxacin. Experimental Acetylsalicylic acid Acetylsalicylic acid may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Adapalene Adapalene may increase the neuroexcitatory activities of Norfloxacin. Approved Albiglutide Norfloxacin may increase the hypoglycemic activities of Albiglutide. Approved Alclofenac Alclofenac may increase the neuroexcitatory activities of Norfloxacin. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Alclometasone is combined with Norfloxacin. Approved Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Norfloxacin. Experimental, Investigational Almasilate Almasilate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Alminoprofen Alminoprofen may increase the neuroexcitatory activities of Norfloxacin. Experimental Alogliptin Norfloxacin may increase the hypoglycemic activities of Alogliptin. Approved Aloglutamol Aloglutamol can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Aluminium Aluminium can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Ambroxol acefyllinate The metabolism of Ambroxol acefyllinate can be decreased when combined with Norfloxacin. Experimental, Investigational Amcinonide The risk or severity of adverse effects can be increased when Amcinonide is combined with Norfloxacin. Approved Aminophylline The metabolism of Aminophylline can be decreased when combined with Norfloxacin. Approved Amiodarone Norfloxacin may increase the QTc-prolonging activities of Amiodarone. Approved, Investigational Anagrelide Norfloxacin may increase the QTc-prolonging activities of Anagrelide. Approved Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Norfloxacin. Approved, Investigational, Withdrawn Andrographolide Andrographolide may increase the neuroexcitatory activities of Norfloxacin. Investigational Androstenedione The risk or severity of adverse effects can be increased when Androstenedione is combined with Norfloxacin. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Anecortave is combined with Norfloxacin. Investigational anecortave acetate The risk or severity of adverse effects can be increased when anecortave acetate is combined with Norfloxacin. Investigational Anisodamine Anisodamine may increase the neuroexcitatory activities of Norfloxacin. Investigational Antipyrine Antipyrine may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Apocynin Apocynin may increase the neuroexcitatory activities of Norfloxacin. Investigational Apremilast Apremilast may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Arsenic trioxide Norfloxacin may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Norfloxacin may increase the QTc-prolonging activities of Artemether. Approved Artesunate The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Norfloxacin resulting in a loss in efficacy. Approved, Investigational Asenapine Norfloxacin may increase the QTc-prolonging activities of Asenapine. Approved Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Norfloxacin. Approved, Investigational, Withdrawn Atamestane The risk or severity of adverse effects can be increased when Atamestane is combined with Norfloxacin. Investigational Atorvastatin The risk or severity of adverse effects can be increased when Norfloxacin is combined with Atorvastatin. Approved Azapropazone Azapropazone may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Azelastine Azelastine may increase the neuroexcitatory activities of Norfloxacin. Approved Azithromycin Norfloxacin may increase the QTc-prolonging activities of Azithromycin. Approved Balsalazide Balsalazide may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Norfloxacin. Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Norfloxacin. Approved, Investigational Bedaquiline Norfloxacin may increase the QTc-prolonging activities of Bedaquiline. Approved Bendazac Bendazac may increase the neuroexcitatory activities of Norfloxacin. Experimental Benorilate Benorilate may increase the neuroexcitatory activities of Norfloxacin. Experimental Benoxaprofen Benoxaprofen may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Benzydamine Benzydamine may increase the neuroexcitatory activities of Norfloxacin. Approved Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Norfloxacin. Approved, Vet Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Norfloxacin. Approved, Investigational Bevonium Bevonium may increase the neuroexcitatory activities of Norfloxacin. Experimental Bismuth Subcitrate Bismuth Subcitrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Norfloxacin. Approved Bromfenac Bromfenac may increase the neuroexcitatory activities of Norfloxacin. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Norfloxacin. Approved, Investigational Bucillamine Bucillamine may increase the neuroexcitatory activities of Norfloxacin. Investigational Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Norfloxacin. Approved Bufexamac Bufexamac may increase the neuroexcitatory activities of Norfloxacin. Approved, Experimental Bumadizone Bumadizone may increase the neuroexcitatory activities of Norfloxacin. Experimental Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Norfloxacin. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Norfloxacin. Approved Caffeine The serum concentration of Caffeine can be increased when it is combined with Norfloxacin. Approved Calcium Acetate Calcium Acetate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Chloride Calcium Chloride can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Citrate Calcium Citrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium glubionate Calcium glubionate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Gluceptate Calcium Gluceptate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Calcium lactate Calcium lactate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Calcium lactate gluconate Calcium lactate gluconate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium levulinate Calcium levulinate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Calcium pangamate Calcium pangamate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium silicate Calcium silicate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Canagliflozin Norfloxacin may increase the hypoglycemic activities of Canagliflozin. Approved Carbaspirin calcium Carbaspirin calcium may increase the neuroexcitatory activities of Norfloxacin. Experimental, Investigational Carprofen Carprofen may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved, Withdrawn Casein Casein can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Castanospermine Castanospermine may increase the neuroexcitatory activities of Norfloxacin. Experimental Celecoxib Celecoxib may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Ceritinib Norfloxacin may increase the QTc-prolonging activities of Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Norfloxacin. Approved, Withdrawn Chloroquine Chloroquine may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Vet Approved Chlorpromazine Norfloxacin may increase the QTc-prolonging activities of Chlorpromazine. Approved, Investigational, Vet Approved Chlorpropamide Norfloxacin may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the neuroexcitatory activities of Norfloxacin. Approved Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Norfloxacin. Approved, Investigational Ciprofloxacin Norfloxacin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride Norfloxacin may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Norfloxacin may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Norfloxacin may increase the QTc-prolonging activities of Clarithromycin. Approved Clobetasol The risk or severity of adverse effects can be increased when Clobetasol is combined with Norfloxacin. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Norfloxacin. Approved Clobetasone The risk or severity of adverse effects can be increased when Clobetasone is combined with Norfloxacin. Approved Clocortolone The risk or severity of adverse effects can be increased when Clocortolone is combined with Norfloxacin. Approved Clonixin Clonixin may increase the neuroexcitatory activities of Norfloxacin. Approved Clorindione Norfloxacin may increase the anticoagulant activities of Clorindione. Experimental Clozapine Norfloxacin may increase the QTc-prolonging activities of Clozapine. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Norfloxacin. Investigational Corticosterone The risk or severity of adverse effects can be increased when Corticosterone is combined with Norfloxacin. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Norfloxacin. Approved, Investigational Crizotinib Norfloxacin may increase the QTc-prolonging activities of Crizotinib. Approved Curcumin Curcumin may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Norfloxacin. Approved, Investigational Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Norfloxacin. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Norfloxacin. Experimental Dapagliflozin Norfloxacin may increase the hypoglycemic activities of Dapagliflozin. Approved Deflazacort The risk or severity of adverse effects can be increased when Deflazacort is combined with Norfloxacin. Approved, Investigational Delamanid Norfloxacin may increase the QTc-prolonging activities of Delamanid. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Norfloxacin. Approved Desonide The risk or severity of adverse effects can be increased when Desonide is combined with Norfloxacin. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Norfloxacin. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Norfloxacin. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Norfloxacin. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Norfloxacin. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Norfloxacin. Vet Approved Diclofenac Diclofenac may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Dicoumarol Norfloxacin may increase the anticoagulant activities of Dicoumarol. Approved Didanosine The serum concentration of Didanosine can be decreased when it is combined with Norfloxacin. Approved Difenpiramide Difenpiramide may increase the neuroexcitatory activities of Norfloxacin. Experimental Diflorasone The risk or severity of adverse effects can be increased when Diflorasone is combined with Norfloxacin. Approved Diflunisal Diflunisal may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Difluocortolone is combined with Norfloxacin. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Difluprednate is combined with Norfloxacin. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Norfloxacin. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Norfloxacin. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Norfloxacin. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Norfloxacin. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Norfloxacin. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Norfloxacin. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Norfloxacin. Approved, Investigational Diphenadione Norfloxacin may increase the anticoagulant activities of Diphenadione. Experimental Disopyramide Norfloxacin may increase the QTc-prolonging activities of Disopyramide. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Norfloxacin. Approved, Investigational Dofetilide Norfloxacin may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron Norfloxacin may increase the QTc-prolonging activities of Dolasetron. Approved, Investigational Domperidone Norfloxacin may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Dronedarone Norfloxacin may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Norfloxacin may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Droxicam Droxicam may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Dulaglutide Norfloxacin may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duvelisib Duvelisib may increase the neuroexcitatory activities of Norfloxacin. Investigational Dyphylline The metabolism of Dyphylline can be decreased when combined with Norfloxacin. Approved E-6201 E-6201 may increase the neuroexcitatory activities of Norfloxacin. Investigational Eliglustat Norfloxacin may increase the QTc-prolonging activities of Eliglustat. Approved Empagliflozin Norfloxacin may increase the hypoglycemic activities of Empagliflozin. Approved Epirizole Epirizole may increase the neuroexcitatory activities of Norfloxacin. Approved Equilenin The risk or severity of adverse effects can be increased when Equilenin is combined with Norfloxacin. Experimental Equilin The risk or severity of adverse effects can be increased when Equilin is combined with Norfloxacin. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Norfloxacin. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Norfloxacin. Approved Erythromycin Norfloxacin may increase the QTc-prolonging activities of Erythromycin. Approved, Investigational, Vet Approved Escitalopram Norfloxacin may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Estrone The risk or severity of adverse effects can be increased when Estrone is combined with Norfloxacin. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Norfloxacin. Approved Etanercept Etanercept may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Ethenzamide Ethenzamide may increase the neuroexcitatory activities of Norfloxacin. Experimental Ethyl biscoumacetate Norfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Etoricoxib Etoricoxib may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Evening primrose oil Evening primrose oil may increase the neuroexcitatory activities of Norfloxacin. Investigational, Nutraceutical Exenatide Norfloxacin may increase the hypoglycemic activities of Exenatide. Approved, Investigational Exisulind Exisulind may increase the neuroexcitatory activities of Norfloxacin. Investigational Felbinac Felbinac may increase the neuroexcitatory activities of Norfloxacin. Experimental Fenbufen Fenbufen may increase the neuroexcitatory activities of Norfloxacin. Approved Fenoprofen Fenoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved Fentiazac Fentiazac may increase the neuroexcitatory activities of Norfloxacin. Experimental Feprazone Feprazone may increase the neuroexcitatory activities of Norfloxacin. Experimental Ferric Carboxymaltose The serum concentration of Norfloxacin can be decreased when it is combined with Ferric Carboxymaltose. Approved Ferric pyrophosphate The serum concentration of Norfloxacin can be decreased when it is combined with Ferric pyrophosphate. Experimental Ferulic acid Ferulic acid may increase the neuroexcitatory activities of Norfloxacin. Experimental Flecainide Norfloxacin may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Floctafenine Floctafenine may increase the neuroexcitatory activities of Norfloxacin. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Fluasterone is combined with Norfloxacin. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Norfloxacin. Approved, Investigational Fluindione Norfloxacin may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone The risk or severity of adverse effects can be increased when Flumethasone is combined with Norfloxacin. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Norfloxacin. Approved, Investigational Flunixin Flunixin may increase the neuroexcitatory activities of Norfloxacin. Vet Approved Flunoxaprofen Flunoxaprofen may increase the neuroexcitatory activities of Norfloxacin. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Norfloxacin. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Norfloxacin. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Norfloxacin. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Norfloxacin. Approved, Investigational Fluoxetine Norfloxacin may increase the QTc-prolonging activities of Fluoxetine. Approved, Vet Approved Flupentixol Norfloxacin may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluprednidene The risk or severity of adverse effects can be increased when Fluprednidene is combined with Norfloxacin. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Norfloxacin. Approved Flurandrenolide The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Norfloxacin. Approved Flurbiprofen Flurbiprofen may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Norfloxacin. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Norfloxacin. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Norfloxacin. Approved Formestane The risk or severity of adverse effects can be increased when Formestane is combined with Norfloxacin. Approved, Investigational, Withdrawn Gadobenic acid Norfloxacin may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Gemifloxacin Norfloxacin may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Norfloxacin. Experimental Gliclazide Norfloxacin may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Norfloxacin may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Norfloxacin may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Norfloxacin may increase the hypoglycemic activities of Glyburide. Approved Goserelin Norfloxacin may increase the QTc-prolonging activities of Goserelin. Approved Granisetron Norfloxacin may increase the QTc-prolonging activities of Granisetron. Approved, Investigational Guacetisal Guacetisal may increase the neuroexcitatory activities of Norfloxacin. Experimental Halcinonide The risk or severity of adverse effects can be increased when Halcinonide is combined with Norfloxacin. Approved, Investigational, Withdrawn Haloperidol Norfloxacin may increase the QTc-prolonging activities of Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when HE3286 is combined with Norfloxacin. Investigational Higenamine Higenamine may increase the neuroexcitatory activities of Norfloxacin. Investigational Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Norfloxacin. Approved, Vet Approved Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Norfloxacin. Approved Ibuprofen Ibuprofen may increase the neuroexcitatory activities of Norfloxacin. Approved Ibuproxam Ibuproxam may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Ibutilide Norfloxacin may increase the QTc-prolonging activities of Ibutilide. Approved Icatibant Icatibant may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Iloperidone Norfloxacin may increase the QTc-prolonging activities of Iloperidone. Approved Imidazole salicylate Imidazole salicylate may increase the neuroexcitatory activities of Norfloxacin. Experimental Indobufen Indobufen may increase the neuroexcitatory activities of Norfloxacin. Investigational Indomethacin Indomethacin may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Indoprofen Indoprofen may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Insulin Aspart Norfloxacin may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Norfloxacin may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Norfloxacin may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Norfloxacin may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Norfloxacin may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Norfloxacin may increase the hypoglycemic activities of Insulin Lispro. Approved Iron The serum concentration of Norfloxacin can be decreased when it is combined with Iron. Approved Iron Dextran The serum concentration of Norfloxacin can be decreased when it is combined with Iron Dextran. Approved, Vet Approved Iron saccharate The serum concentration of Norfloxacin can be decreased when it is combined with Iron saccharate. Approved Isoxicam Isoxicam may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Istaroxime is combined with Norfloxacin. Investigational Kebuzone Kebuzone may increase the neuroexcitatory activities of Norfloxacin. Experimental Ketoprofen Ketoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Ketorolac Ketorolac may increase the neuroexcitatory activities of Norfloxacin. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Norfloxacin. Experimental Lanthanum carbonate The serum concentration of Norfloxacin can be decreased when it is combined with Lanthanum carbonate. Approved Leflunomide Leflunomide may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Lenvatinib Norfloxacin may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Leuprolide Norfloxacin may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levofloxacin Norfloxacin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Liraglutide Norfloxacin may increase the hypoglycemic activities of Liraglutide. Approved Lisofylline Lisofylline may increase the neuroexcitatory activities of Norfloxacin. Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Norfloxacin. Approved, Investigational Lonazolac Lonazolac may increase the neuroexcitatory activities of Norfloxacin. Experimental Lopinavir Norfloxacin may increase the QTc-prolonging activities of Lopinavir. Approved Lornoxicam Lornoxicam may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Loteprednol The risk or severity of adverse effects can be increased when Loteprednol is combined with Norfloxacin. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Norfloxacin. Approved, Investigational Loxoprofen Loxoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Lumefantrine Norfloxacin may increase the QTc-prolonging activities of Lumefantrine. Approved Lumiracoxib Lumiracoxib may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Norfloxacin. Illicit, Investigational, Withdrawn Magaldrate Magaldrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium salicylate The serum concentration of Norfloxacin can be decreased when it is combined with Magnesium salicylate. Approved Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium sulfate The serum concentration of Norfloxacin can be decreased when it is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Masoprocol Masoprocol may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when ME-609 is combined with Norfloxacin. Investigational Mecasermin Norfloxacin may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Meclofenamic acid Meclofenamic acid may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Medrysone is combined with Norfloxacin. Approved Mefenamic acid Mefenamic acid may increase the neuroexcitatory activities of Norfloxacin. Approved Melengestrol The risk or severity of adverse effects can be increased when Melengestrol is combined with Norfloxacin. Vet Approved Meloxicam Meloxicam may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Mesalazine Mesalazine may increase the neuroexcitatory activities of Norfloxacin. Approved Metamizole Metamizole may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Norfloxacin. Experimental Metformin Norfloxacin may increase the hypoglycemic activities of Metformin. Approved Methadone Norfloxacin may increase the QTc-prolonging activities of Methadone. Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Norfloxacin. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Norfloxacin. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Norfloxacin. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Norfloxacin. Experimental Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Norfloxacin. Experimental Mifepristone Mifepristone may increase the QTc-prolonging activities of Norfloxacin. Approved, Investigational Miglitol Norfloxacin may increase the hypoglycemic activities of Miglitol. Approved Mizoribine Mizoribine may increase the neuroexcitatory activities of Norfloxacin. Investigational Mofebutazone Mofebutazone may increase the neuroexcitatory activities of Norfloxacin. Experimental Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Norfloxacin. Approved, Vet Approved Moxifloxacin Norfloxacin may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil Mycophenolate mofetil may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Norfloxacin. Approved Nabumetone Nabumetone may increase the neuroexcitatory activities of Norfloxacin. Approved Nafamostat Nafamostat may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Naftifine Naftifine may increase the neuroexcitatory activities of Norfloxacin. Approved Naproxen Naproxen may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Nateglinide Norfloxacin may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when NCX 1022 is combined with Norfloxacin. Investigational Nepafenac Nepafenac may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Norfloxacin. Approved, Investigational Nifenazone Nifenazone may increase the neuroexcitatory activities of Norfloxacin. Experimental Niflumic Acid Niflumic Acid may increase the neuroexcitatory activities of Norfloxacin. Approved Nilotinib Norfloxacin may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nimesulide Nimesulide may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Withdrawn Nitroaspirin Nitroaspirin may increase the neuroexcitatory activities of Norfloxacin. Investigational Nitrofurantoin The therapeutic efficacy of Norfloxacin can be decreased when used in combination with Nitrofurantoin. Approved, Vet Approved Ofloxacin Norfloxacin may increase the QTc-prolonging activities of Ofloxacin. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Norfloxacin. Experimental, Investigational Oleoyl-estrone The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Norfloxacin. Investigational Olopatadine Olopatadine may increase the neuroexcitatory activities of Norfloxacin. Approved Olsalazine Olsalazine may increase the neuroexcitatory activities of Norfloxacin. Approved Ondansetron Norfloxacin may increase the QTc-prolonging activities of Ondansetron. Approved Orgotein Orgotein may increase the neuroexcitatory activities of Norfloxacin. Vet Approved Ouabain Ouabain may decrease the cardiotoxic activities of Norfloxacin. Approved Oxaprozin Oxaprozin may increase the neuroexcitatory activities of Norfloxacin. Approved Oxyphenbutazone Oxyphenbutazone may increase the neuroexcitatory activities of Norfloxacin. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Norfloxacin. Approved, Vet Approved Paliperidone Norfloxacin may increase the QTc-prolonging activities of Paliperidone. Approved Panobinostat Norfloxacin may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational Paramethasone The risk or severity of adverse effects can be increased when Paramethasone is combined with Norfloxacin. Approved Parecoxib Parecoxib may increase the neuroexcitatory activities of Norfloxacin. Approved Parthenolide Parthenolide may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Pazopanib Norfloxacin may increase the QTc-prolonging activities of Pazopanib. Approved Pentamidine Norfloxacin may increase the QTc-prolonging activities of Pentamidine. Approved, Investigational Perflutren Norfloxacin may increase the QTc-prolonging activities of Perflutren. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Norfloxacin. Approved, Investigational, Vet Approved, Withdrawn Peruvoside Peruvoside may decrease the cardiotoxic activities of Norfloxacin. Experimental Phenindione Norfloxacin may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Norfloxacin may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone Phenylbutazone may increase the neuroexcitatory activities of Norfloxacin. Approved, Vet Approved Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Norfloxacin. Approved Pimecrolimus Pimecrolimus may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Pimozide Norfloxacin may increase the QTc-prolonging activities of Pimozide. Approved Pioglitazone Norfloxacin may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pirfenidone Pirfenidone may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Piroxicam Piroxicam may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Pirprofen Pirprofen may increase the neuroexcitatory activities of Norfloxacin. Experimental Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Norfloxacin. Approved Pramlintide Norfloxacin may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Pranoprofen Pranoprofen may increase the neuroexcitatory activities of Norfloxacin. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Norfloxacin. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Norfloxacin. Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Norfloxacin. Approved Prednicarbate The risk or severity of adverse effects can be increased when Prednicarbate is combined with Norfloxacin. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Norfloxacin. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Norfloxacin. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Pregnenolone is combined with Norfloxacin. Approved, Experimental, Investigational Primaquine Norfloxacin may increase the QTc-prolonging activities of Primaquine. Approved Probenecid The serum concentration of Norfloxacin can be increased when it is combined with Probenecid. Approved, Investigational Procainamide Norfloxacin may increase the QTc-prolonging activities of Procainamide. Approved Proglumetacin Proglumetacin may increase the neuroexcitatory activities of Norfloxacin. Experimental Promazine Norfloxacin may increase the QTc-prolonging activities of Promazine. Approved, Vet Approved Propacetamol Propacetamol may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Propafenone Norfloxacin may increase the QTc-prolonging activities of Propafenone. Approved Propyphenazone Propyphenazone may increase the neuroexcitatory activities of Norfloxacin. Experimental Proquazone Proquazone may increase the neuroexcitatory activities of Norfloxacin. Experimental Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Norfloxacin. Experimental PTC299 PTC299 may increase the neuroexcitatory activities of Norfloxacin. Investigational Quetiapine Norfloxacin may increase the QTc-prolonging activities of Quetiapine. Approved Quinapril Quinapril can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Quinidine Norfloxacin may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Norfloxacin may increase the QTc-prolonging activities of Quinine. Approved Repaglinide Norfloxacin may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Resveratrol Resveratrol may increase the neuroexcitatory activities of Norfloxacin. Approved, Experimental, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Norfloxacin. Approved Rimexolone The risk or severity of adverse effects can be increased when Rimexolone is combined with Norfloxacin. Approved Rofecoxib Rofecoxib may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Withdrawn Rosiglitazone Norfloxacin may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Norfloxacin. Approved Salicylamide Salicylamide may increase the neuroexcitatory activities of Norfloxacin. Approved Salicylic acid Salicylic acid may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Vet Approved Salsalate Salsalate may increase the neuroexcitatory activities of Norfloxacin. Approved Saquinavir Norfloxacin may increase the QTc-prolonging activities of Saquinavir. Approved, Investigational Saxagliptin Norfloxacin may increase the hypoglycemic activities of Saxagliptin. Approved Semapimod Semapimod may increase the neuroexcitatory activities of Norfloxacin. Investigational Seratrodast Seratrodast may increase the neuroexcitatory activities of Norfloxacin. Approved Serrapeptase Serrapeptase may increase the neuroexcitatory activities of Norfloxacin. Investigational Sevelamer Sevelamer can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Norfloxacin. Approved Sitagliptin Norfloxacin may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sotalol Norfloxacin may increase the QTc-prolonging activities of Sotalol. Approved SRT501 SRT501 may increase the neuroexcitatory activities of Norfloxacin. Investigational Strontium ranelate The serum concentration of Norfloxacin can be decreased when it is combined with Strontium ranelate. Approved, Withdrawn Sucralfate The serum concentration of Norfloxacin can be decreased when it is combined with Sucralfate. Approved Sulfadiazine Norfloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Norfloxacin may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfasalazine Sulfasalazine may increase the neuroexcitatory activities of Norfloxacin. Approved Sulfisoxazole Norfloxacin may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Sulindac Sulindac may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Sunitinib Norfloxacin may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Suprofen Suprofen may increase the neuroexcitatory activities of Norfloxacin. Approved, Withdrawn Suxibuzone Suxibuzone may increase the neuroexcitatory activities of Norfloxacin. Experimental Tarenflurbil Tarenflurbil may increase the neuroexcitatory activities of Norfloxacin. Investigational Telavancin Norfloxacin may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Norfloxacin may increase the QTc-prolonging activities of Telithromycin. Approved Tenidap Tenidap may increase the neuroexcitatory activities of Norfloxacin. Experimental Tenoxicam Tenoxicam may increase the neuroexcitatory activities of Norfloxacin. Approved Tepoxalin Tepoxalin may increase the neuroexcitatory activities of Norfloxacin. Vet Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Norfloxacin. Experimental Teriflunomide Teriflunomide may increase the neuroexcitatory activities of Norfloxacin. Approved Tetrabenazine Norfloxacin may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Theophylline The metabolism of Theophylline can be decreased when combined with Norfloxacin. Approved Thioridazine Norfloxacin may increase the QTc-prolonging activities of Thioridazine. Approved, Withdrawn Tiaprofenic acid Tiaprofenic acid may increase the neuroexcitatory activities of Norfloxacin. Approved Tinoridine Tinoridine may increase the neuroexcitatory activities of Norfloxacin. Investigational Tioclomarol Norfloxacin may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol The risk or severity of adverse effects can be increased when Tixocortol is combined with Norfloxacin. Approved, Withdrawn Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Norfloxacin. Approved, Investigational Tolazamide Norfloxacin may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Norfloxacin may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid Tolfenamic Acid may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Tolmetin Tolmetin may increase the neuroexcitatory activities of Norfloxacin. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Norfloxacin. Approved Toremifene Norfloxacin may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tranilast Tranilast may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Norfloxacin. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Norfloxacin. Approved, Vet Approved Tribenoside Tribenoside may increase the neuroexcitatory activities of Norfloxacin. Experimental Triptolide Triptolide may increase the neuroexcitatory activities of Norfloxacin. Investigational Tromethamine Tromethamine can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ulobetasol The risk or severity of adverse effects can be increased when Ulobetasol is combined with Norfloxacin. Approved Valdecoxib Valdecoxib may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Withdrawn Vandetanib Norfloxacin may increase the QTc-prolonging activities of Vandetanib. Approved Varenicline The serum concentration of Varenicline can be increased when it is combined with Norfloxacin. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Norfloxacin. Approved Warfarin Norfloxacin may increase the anticoagulant activities of Warfarin. Approved Zaltoprofen Zaltoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational Zileuton Zileuton may increase the neuroexcitatory activities of Norfloxacin. Approved, Investigational, Withdrawn Ziprasidone Norfloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved Zomepirac Zomepirac may increase the neuroexcitatory activities of Norfloxacin. Withdrawn Zuclopenthixol Norfloxacin may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Avoid high doses of caffeine.
- Take on an empty stomach. Drink liberally.
References
- Synthesis Reference
- US4146719
- General References
- Goldstein EJ: Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. Am J Med. 1987 Jun 26;82(6B):3-17. [PubMed:3111257]
- External Links
- Human Metabolome Database
- HMDB0015192
- KEGG Drug
- D00210
- KEGG Compound
- C06687
- PubChem Compound
- 4539
- PubChem Substance
- 46508634
- ChemSpider
- 4380
- BindingDB
- 50045000
- ChEBI
- 100246
- ChEMBL
- CHEMBL9
- Therapeutic Targets Database
- DAP000654
- PharmGKB
- PA450654
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Norfloxacin
- ATC Codes
- S01AE02 — NorfloxacinJ01RA13 — Norfloxacin and tinidazole
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- AHFS Codes
- 52:04.04 — Antibacterials
- 08:12.18 — Quinolones
- FDA label
- Download (599 KB)
- MSDS
- Download (42.5 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Recruiting Treatment Osteomyelitis 1 2 Completed Treatment Hepatopulmonary Syndrome 1 2, 3 Unknown Status Prevention Liver Cirrhosis / Spontaneous Bacterial Peritonitis (SBP) 1 3 Completed Prevention Cirrhosis With Ascites 1 3 Recruiting Prevention Ascites / Liver Cirrhosis / Spontaneous Bacterial Peritonitis (SBP) 1 3 Terminated Prevention Liver Cirrhosis 1 3 Withdrawn Treatment Cystitis 1 4 Completed Prevention Adverse Reaction to Other Drugs and Medicines 1 4 Completed Prevention Hepatorenal Syndrome / Liver Cirrhosis / Spontaneous Bacterial Peritonitis (SBP) 1 4 Not Yet Recruiting Treatment Urinary Tract Infections (UTIs) 1 4 Terminated Treatment Urinary Tract Infections (UTIs) 1 Not Available Unknown Status Treatment Portal Hypertension 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amerisource Health Services Corp.
- Merck & Co.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Shire Inc.
- Dosage forms
Form Route Strength Tablet Oral 400 mg Solution Ophthalmic 3 mg - Prices
Unit description Cost Unit Noroxin 400 mg tablet 4.21USD tablet Apo-Norflox 400 mg Tablet 1.44USD tablet Co Norfloxacin 400 mg Tablet 1.28USD tablet Novo-Norfloxacin 400 mg Tablet 1.28USD tablet Pms-Norfloxacin 400 mg Tablet 1.28USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 227-228 °C PhysProp water solubility 1.78E+005 mg/L Not Available logP -1.03 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 1.01 mg/mL ALOGPS logP -0.47 ALOGPS logP -0.92 ChemAxon logS -2.5 ALOGPS pKa (Strongest Acidic) 5.77 ChemAxon pKa (Strongest Basic) 8.68 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 72.88 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 85.48 m3·mol-1 ChemAxon Polarizability 32.26 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9916 Blood Brain Barrier - 0.9824 Caco-2 permeable - 0.8683 P-glycoprotein substrate Substrate 0.8554 P-glycoprotein inhibitor I Non-inhibitor 0.849 P-glycoprotein inhibitor II Non-inhibitor 0.8657 Renal organic cation transporter Non-inhibitor 0.7588 CYP450 2C9 substrate Non-substrate 0.8301 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.7558 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.9268 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9148 CYP450 3A4 inhibitor Non-inhibitor 0.8988 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5702 Ames test AMES toxic 0.9108 Carcinogenicity Non-carcinogens 0.7923 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.8785 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7034 hERG inhibition (predictor II) Non-inhibitor 0.5292
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Benzenoids / Aryl fluorides show 12 more
- Substituents
- Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Tertiary aliphatic/aromatic amine show 29 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- N-arylpiperazine, quinolone antibiotic, fluoroquinolone antibiotic, quinolone, quinolinemonocarboxylic acid (CHEBI:100246) / Fluoroquinolones (C06687)
Targets
- Kind
- Protein
- Organism
- Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Dna topoisomerase type ii (atp-hydrolyzing) activity
- Specific Function
- Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
- Gene Name
- parC
- Uniprot ID
- P43702
- Uniprot Name
- DNA topoisomerase 4 subunit A
- Molecular Weight
- 83366.24 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. [PubMed:15673722]
- Vila J, Sanchez-Cespedes J, Sierra JM, Piqueras M, Nicolas E, Freixas J, Giralt E: Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria. Int J Antimicrob Agents. 2006 Jul;28(1):19-24. Epub 2006 Jun 14. [PubMed:16781123]
- Oyamada Y, Ito H, Fujimoto K, Asada R, Niga T, Okamoto R, Inoue M, Yamagishi J: Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol. 2006 Jun;55(Pt 6):729-36. [PubMed:16687591]
- Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187]
- Kind
- Protein
- Organism
- Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Dna topoisomerase type ii (atp-hydrolyzing) activity
- Specific Function
- DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
- Gene Name
- gyrA
- Uniprot ID
- P43700
- Uniprot Name
- DNA gyrase subunit A
- Molecular Weight
- 97817.145 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Hombrouck C, Capmau ML, Moreau N: Overexpression, purification and photoaffinity labeling with a 3H-analogue of norfloxacin, of the GyrA and GyrB subunits of the DNA gyrase. Cell Mol Biol (Noisy-le-grand). 1999 May;45(3):347-52. [PubMed:10386791]
- Hooper DC: Quinolone mode of action--new aspects. Drugs. 1993;45 Suppl 3:8-14. [PubMed:7689456]
- Fukuda H, Hori S, Hiramatsu K: Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22. [PubMed:9687384]
- Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Ubiquitin binding
- Specific Function
- Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
- Gene Name
- TOP2A
- Uniprot ID
- P11388
- Uniprot Name
- DNA topoisomerase 2-alpha
- Molecular Weight
- 174383.88 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Vitamin d 24-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A1
- Uniprot ID
- P04798
- Uniprot Name
- Cytochrome P450 1A1
- Molecular Weight
- 58164.815 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
- Gene Name
- SLC22A5
- Uniprot ID
- O76082
- Uniprot Name
- Solute carrier family 22 member 5
- Molecular Weight
- 62751.08 Da
References
- Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577]
Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:48